Bladder cancer treatment after BCG therapy fails
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with non-muscle-invasive bladder cancer that has not responded to BCG treatment.
- You have had a complete transurethral resection of the bladder tumor (TURBT) before starting the trial.
- Your cancer is considered intermediate or high risk by current guidelines.
- You are fit enough to receive intravesical chemotherapy (drugs given directly into the bladder).
- You have adequate organ function (bone marrow, kidneys, liver) and a good performance status (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This trial tests a combination of an immunotherapy drug (toripalimab) with or without two chemotherapy drugs placed directly into the bladder (gemcitabine and mitomycin C). It is for people whose high-risk bladder cancer did not respond to or could not tolerate BCG treatment.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests whether injecting gemcitabine into the bladder lining during tumor removal surgery can help prevent the cancer from coming back in people with intermediate- or high-risk non-muscle-invasive bladder cancer.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.